PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor
February 27, 2023 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer
December 15, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable
October 27, 2022 08:00 ET
|
PDS Biotechnology Corporation
Jared Weiss, MD, Lead Investigator for the VERSATILE-002 clinical trial combining PDS0101 and KEYTRUDA®, presents interim data from the study Combination shows potential to achieve oncologists’ goals...
PDS Biotech Chief Medical Officer Dr. Lauren V. Wood to Address 2022 International Head and Neck Conference
October 25, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
CORRECTION -- OmniPathology Announces the Launch of its Oropharyngeal HPV PCR Test
July 12, 2022 14:55 ET
|
OmniPathology
PASADENA, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by OmniPathology, please note that the second sentence in paragraph one should read "The...
OmniPathology Announces the Launch of its Oropharyngeal HPV PCR Test
July 12, 2022 08:45 ET
|
OmniPathology
PASADENA, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- OmniPathology, an independent, physician-owned and operated pathology lab, today announced the launch of a new oral test for human papillomavirus...
HPV Vaccine Market: 5.73B by 2028, Human Papillomavirus Vaccine Market Growing at 5% CAGR Lead by 9-Valent HPV Vaccine Segment, Global Analysis by The Insight Partners
June 17, 2022 08:26 ET
|
The Insight Partners
New York, June 17, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Human Papillomavirus (HPV) Vaccine Market Size, Share, Growth, Revenue, Trends, Forecast to 2028...
Baum Hedlund Issues Guide for Gardasil Injury Victims
June 10, 2022 12:07 ET
|
Baum Hedlund Aristei & Goldman
Los Angeles, California, June 10, 2022 (GLOBE NEWSWIRE) -- Personal injury lawyers from the Baum Hedlund law firm have released a new Gardasil Injury Compensation Guide to help victims who allege...
HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO
June 05, 2022 09:00 ET
|
HOOKIPA Pharma Inc.
Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tumor activity and similar tolerability vs. single-vector therapyPhase 2 to proceed with alternating...
Warts Therapeutics Market Size to Outstrip $2,314.60Mn by 2028 Growth Projections at 3.4% CAGR During 2021 to 2028 COVID Impact and Global Analysis by TheInsightPartners.com
September 28, 2021 14:49 ET
|
The Insight Partners
New York, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Warts Therapeutics Market: Key InsightsAccording to our new research study on “Warts Therapeutics Market to 2028 – Global Analysis and Forecast – by...